Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23212293 | 1.00 | KMT2A (0.43) | KMT2AMEN1TP53KDM4ELMNA | |
| SCHEMBL3823391 | 0.80 | MEN1 (0.47) | KMT2AMEN1KDM4ELMNAHTT | |
| SCHEMBL24173162 | 0.74 | CACNA2D1 (0.64) | CACNA2D1 | |
| SCHEMBL15457139 | 0.74 | KDM4E (0.50) | KMT2AMEN1KDM4ELMNAHTT | |
| SCHEMBL23212406 | 0.74 | CACNA2D1 (0.51) | CACNA2D1 | |
| SCHEMBL23212831 | 0.74 | CACNA2D1 (0.51) | CACNA2D1 | |
| SCHEMBL23212404 | 0.74 | CACNA2D1 (0.51) | CACNA2D1 | |
| SCHEMBL23212833 | 0.74 | CACNA2D1 (0.51) | CACNA2D1 | |
| SCHEMBL23212399 | 0.74 | CACNA2D1 (0.51) | CACNA2D1 | |
| SCHEMBL23212301 | 0.73 | CACNA2D1 (0.57) | CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479830-B2 | Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2025-11-25 | — | — | US | disclosed |
| CN-114502549-B | Homopiperazinyl and homopiperidinyl quinazolin-4 (3H) -one derivatives having multimodal activity against pain | 埃斯特韦制药股份公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20220380345-A1 | HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-12-01 | — | — | US | disclosed |
| EP-4041391-A1 | HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502549-A | Homopiperazinyl and homopiperidinyl quinazolin-4 (3H) -one derivatives having multimodal activity against pain | 埃斯特韦制药股份公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20220002314-A1 | PIPERAZINYL AND PIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING ACTIVITY AGAINST PAIN | ACONDICIONAMIENTO TARRASENSE (ES) | 2022-01-06 | — | — | US | disclosed |
| CN-113260614-A | Piperazinyl and piperidinyl quinazolin-4 (3H) -one derivatives active against pain | 塔拉森斯调节公司 | 2021-08-13 | — | — | CN | disclosed |
| WO-2021069339-A1 | HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479830-B2 | Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain | OPRD1, SIGMAR1, OPRK1 | KMT2A 4116/4885MEN1 4434/4885TP53 4770/4885 |
| US-20220380345-A1 | HOMOPIPERAZINYL AND HOMOPIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | KMT2A 4116/4885MEN1 4434/4885TP53 4770/4885 |
| US-20220002314-A1 | PIPERAZINYL AND PIPERIDINYL QUINAZOLIN-4(3H)-ONE DERIVATIVES HAVING ACTIVITY AGAINST PAIN | OPRD1, TRPV1, OPRK1 | KMT2A 2036/4885MEN1 4856/4885TP53 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.